Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
8 studies found for:    17167137 [PUBMED-IDS]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: MK-3475;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Pemetrexed
2 Recruiting Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer
Condition: Non-small-cell Lung Cancer
Interventions: Drug: Nimotuzumab;   Drug: docetaxel and cisplatin;   Radiation: daily RT (65Gy in 25 fractions) to the chest;   Drug: placebo
3 Recruiting Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab
Condition: Non-Small Cell Lung Cancer (NSCLC)
Intervention: Drug: gemcitabine, cisplatin and bevacizumab
4 Recruiting Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy
Condition: Squamous Cell Lung Cancer
Interventions: Drug: Boanmycin;   Drug: Docetaxel
5 Withdrawn A Study of Bevacizumab to Prevent Malignant Ascites
Condition: Malignant Ascites
Intervention: Drug: Bevacizumab
6 Completed
Has Results 		A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer
Condition: Tumors
Interventions: Drug: Fosbretabulin;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Bevacizumab
7 Completed Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy
Condition: Lung Cancer
Intervention: Drug: Bortezomib
8 Completed Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Biological: bevacizumab;   Other: laboratory biomarker analysis
To Top

† Indicates status has not been verified in more than two years